BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441-4447. [PMID: 16983112 DOI: 10.1200/jco.2006.07.0201] [Cited by in Crossref: 189] [Cited by in F6Publishing: 74] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Kindler HL. Pancreatic cancer: an update. Curr Oncol Rep 2007;9:170-6. [PMID: 17430687 DOI: 10.1007/s11912-007-0018-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
2 Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622. [PMID: 20606091 DOI: 10.1200/jco.2010.28.1386] [Cited by in Crossref: 562] [Cited by in F6Publishing: 331] [Article Influence: 46.8] [Reference Citation Analysis]
3 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 64] [Article Influence: 13.3] [Reference Citation Analysis]
4 Chiramel J, Backen AC, Pihlak R, Lamarca A, Frizziero M, Tariq NU, Hubner RA, Valle JW, Amir E, McNamara MG. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci 2017;18:E909. [PMID: 28445400 DOI: 10.3390/ijms18050909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
5 Whittle MC, Hingorani SR. Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. Cancer J 2017;23:326-32. [PMID: 29189328 DOI: 10.1097/PPO.0000000000000289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
7 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
8 Zhang S, Xie W, Zou Y, Xie S, Zhang J, Yuan W, Ma J, Zhao J, Zheng C, Chen Y, Wang C. First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis. Cancer Manag Res 2018;10:5965-78. [PMID: 30538546 DOI: 10.2147/CMAR.S162980] [Reference Citation Analysis]
9 Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
10 Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32. [PMID: 20198462 DOI: 10.1208/s12248-010-9181-5] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
11 Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C. Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Manag Res 2017;9:141-8. [PMID: 28461766 DOI: 10.2147/CMAR.S126073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
12 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Okamoto Y, Maeba T, Kakinoki K, Okano K, Izuishi K, Wakabayashi H, Usuki H, Suzuki Y. A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy. World J Gastroenterol. 2008;14:6876-6880. [PMID: 19058319 DOI: 10.3748/wjg.14.6876] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
15 Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med 2015;4:1224-39. [PMID: 25766842 DOI: 10.1002/cam4.444] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
16 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:2784-2796. [PMID: 27247222 DOI: 10.1200/jco.2016.67.1412] [Cited by in Crossref: 166] [Cited by in F6Publishing: 90] [Article Influence: 27.7] [Reference Citation Analysis]
18 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
19 Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials. Biomedicines 2016;4:E20. [PMID: 28536387 DOI: 10.3390/biomedicines4030020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
20 Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 2010;7:307-49. [PMID: 20108971 DOI: 10.1021/mp900243b] [Cited by in Crossref: 238] [Cited by in F6Publishing: 209] [Article Influence: 19.8] [Reference Citation Analysis]
21 Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, Ni ZL, Liu HB, Guo HC, Liu DL. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS One 2012;7:e42146. [PMID: 22876305 DOI: 10.1371/journal.pone.0042146] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
22 Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther. 2016;15:680-688. [PMID: 26832793 DOI: 10.1158/1535-7163.mct-15-0764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
23 Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
24 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
25 Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. [PMID: 18316569 DOI: 10.1158/1078-0432.ccr-07-0371] [Cited by in Crossref: 225] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
26 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
27 Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. J Transl Med 2013;11:291. [PMID: 24237633 DOI: 10.1186/1479-5876-11-291] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
28 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.66 04436] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, Donahue T, Hines OJ. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Target Oncol 2018;13:461-8. [PMID: 29882102 DOI: 10.1007/s11523-018-0572-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
30 Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009;27:629-33. [PMID: 19064977 DOI: 10.1200/JCO.2008.17.8905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
31 Choi JG, Seo JH, Oh SC, Choi CW, Kim JS. A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2012;44:127-132. [PMID: 22802751 DOI: 10.4143/crt.2012.44.2.127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
32 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. [PMID: 24131140 DOI: 10.1056/NEJMoa1304369] [Cited by in Crossref: 3143] [Cited by in F6Publishing: 1689] [Article Influence: 349.2] [Reference Citation Analysis]
33 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
34 Blanco VM, Latif T, Chu Z, Qi X. Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol 2015;8:196-203. [PMID: 26055177 DOI: 10.1016/j.tranon.2015.03.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
35 Thota R, Maitra A, Berlin JD. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas 2017;46:143-50. [PMID: 28085753 DOI: 10.1097/MPA.0000000000000753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 2018;19:e151-60. [PMID: 29508762 DOI: 10.1016/S1470-2045(18)30098-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
37 Lin X, Huang M, Xie F, Zhou H, Yang J, Huang Q. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. Oncotarget 2016;7:70092-9. [PMID: 27602753 DOI: 10.18632/oncotarget.11780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
38 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
39 Vogel A, Römmler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016;16:817. [PMID: 27769210 DOI: 10.1186/s12885-016-2798-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
40 Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol 2017;47:832-9. [PMID: 28541474 DOI: 10.1093/jjco/hyx075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
41 Wei WT, Chen H, Wang ZH, Ni ZL, Liu HB, Tong HF, Guo HC, Liu DL, Lin SZ. Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci 2012;8:1-14. [PMID: 22211100 DOI: 10.7150/ijbs.8.1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
42 Shi Y, He Z, Jia Z, Xu C. Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Mol Med Rep 2016;14:2921-8. [PMID: 27499118 DOI: 10.3892/mmr.2016.5592] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
43 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7:e1000307. [PMID: 20644708 DOI: 10.1371/journal.pmed.1000307] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 12.6] [Reference Citation Analysis]
44 Lichota A, Gwozdzinski K. Anticancer Activity of Natural Compounds from Plant and Marine Environment. Int J Mol Sci 2018;19:E3533. [PMID: 30423952 DOI: 10.3390/ijms19113533] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 26.3] [Reference Citation Analysis]
45 Shah N, Zhai G, Knowles JA, Stockard CR, Grizzle WE, Fineberg N, Zhou T, Zinn KR, Rosenthal EL, Kim H. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol 2012;14:237-44. [PMID: 21494920 DOI: 10.1007/s11307-011-0491-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
46 Yanagihara K, Kubo T, Mihara K, Kuwata T, Ochiai A, Seyama T, Yokozaki H. Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line. Pancreas 2019;48:315-22. [PMID: 30747829 DOI: 10.1097/MPA.0000000000001253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
47 Sahai V, Saif MW, Kalyan A, Philip PA, Rocha-Lima CM, Ocean A, Ondovik MS, Simeone DM, Banerjee S, Bhore R, Louis CU, Picozzi V. A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer. J Pancreat Cancer 2019;5:35-42. [PMID: 31559379 DOI: 10.1089/pancan.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
48 Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7:469-478. [PMID: 27284481 DOI: 10.21037/jgo.2016.01.03] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
49 Schmalz V, Koert U. Visible-Light-Induced Photoannulation of α-Naphthyl Cyclopropane Carboxylic Esters to Functionalized Dihydrophenalenes. Org Lett 2021. [PMID: 34932368 DOI: 10.1021/acs.orglett.1c03784] [Reference Citation Analysis]
50 Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, Naoe Y, Ichinose T, Koyama N, Tanaka M, Kodera Y, Goto H. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 2018;18:596. [PMID: 29801474 DOI: 10.1186/s12885-018-4453-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
51 Kim EJ, Semrad TJ, Bold RJ. Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs. 2015;24:781-794. [PMID: 25809274 DOI: 10.1517/13543784.2015.1026963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
52 Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010;59:1527-34. [PMID: 20947887 DOI: 10.1136/gut.2010.216135] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
53 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
54 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Shitara K, Baba E, Fujitani K, Oki E, Fujii S, Yamaguchi K. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 2021;24:780-9. [PMID: 33997928 DOI: 10.1007/s10120-021-01196-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Angst E, Reber HA, Hines OJ, Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008;144:57-65. [PMID: 18571585 DOI: 10.1016/j.surg.2008.03.024] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
57 Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 2015;9:3767-77. [PMID: 26244011 DOI: 10.2147/DDDT.S88023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
58 Giuliani J, Bonetti A. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology 2019;19:325-30. [DOI: 10.1016/j.pan.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
59 Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2008;2:83-95. [PMID: 19707431 DOI: 10.2147/btt.s1832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 31] [Article Influence: 0.1] [Reference Citation Analysis]
60 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Lawrence B, Findlay M. Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol 2010;2:85-106. [PMID: 21789129 DOI: 10.1177/1758834009357188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
62 Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321-337. [PMID: 23814611 DOI: 10.1177/1756283x13478680] [Cited by in Crossref: 155] [Cited by in F6Publishing: 104] [Article Influence: 17.2] [Reference Citation Analysis]
63 Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-1972. [PMID: 27358556 DOI: 10.2147/dddt.s105442] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
64 Xu J, Singh A, Amiji MM. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. BMC Cancer. 2014;14:75. [PMID: 24507760 DOI: 10.1186/1471-2407-14-75] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
65 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
66 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
67 Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;12:7291-7309. [PMID: 29042776 DOI: 10.2147/ijn.s146315] [Cited by in Crossref: 385] [Cited by in F6Publishing: 124] [Article Influence: 77.0] [Reference Citation Analysis]
68 Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011;2011:267539. [PMID: 21922022 DOI: 10.1155/2011/267539] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
69 Qiao Z, Yuan J, Shen J, Wang C, He Z, Hu Y, Zhang M, Xu C. Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo. Oncol Lett 2015;9:2353-60. [PMID: 26137070 DOI: 10.3892/ol.2015.3064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
70 Savage P, Stebbing J, Bower M, Crook T. Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 2009;6:43-52. [PMID: 18982000 DOI: 10.1038/ncponc1260] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 5.9] [Reference Citation Analysis]
71 Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008;99:6-13. [PMID: 18577990 DOI: 10.1038/sj.bjc.6604436] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
72 Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
73 Akinleye A, Iragavarapu C, Furqan M, Cang S, Liu D. Novel agents for advanced pancreatic cancer. Oncotarget 2015;6:39521-37. [PMID: 26369833 DOI: 10.18632/oncotarget.3999] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
74 Pathy S, Chander S. Chemoradiotherapy in pancreatic carcinoma. Indian J Med Paediatr Oncol. 2009;30:55-60. [PMID: 20596304 DOI: 10.4103/0971-5851.60049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Mountzios G, Syrigos KN. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. Drug Saf 2011;34:175-86. [PMID: 21332242 DOI: 10.2165/11586540-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
76 Chen J, Chen L, Yu J, Xu Y, Wang X, Zeng Z, Liu N, Xu F, Yang S. Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities. Mol Med Rep 2019;19:477-89. [PMID: 30431091 DOI: 10.3892/mmr.2018.9638] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011;4:11. [PMID: 21439076 DOI: 10.1186/1756-8722-4-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
78 Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009;11:290-301. [PMID: 19451062 DOI: 10.1007/s12094-009-0357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]